Prospera may provide additional information to better manage COVID-19 patients
Access Prospera remotely through our nationwide mobile phlebotomy program to better manage your transplant patients at risk for COVID-19.
In this publication, Dr. Suphamai Bunnapradist from the University of California Los Angeles highlights a 50 year old female with end stage renal disease and an 11-month transplanted kidney.
Within 48 hours, the patient tested positive for SARS-CoV-2 virus and was serially tested with the Prospera Transplant Assessment test over the 55 days during her hospital stay.
See how Prospera led to better informed care in COVID patients
How ProReach and Prospera work together
Experience the continuity, connection, and convenience of staying close with your transplant patients, particularly those concerned about in-office visits due to immunosuppression and COVID-19.
